India Tightens Rules on Unproven Stem Cell Therapy

India Tightens Stem Cell Therapy Rules, Unapproved Treatments Barred From Routine Clinical Use

India’s Ministry of Health and Family Welfare has issued an advisory calling for stricter compliance with existing rules governing stem cell research and therapy.

The advisory, dated September 16, 2026, was issued to States and Union Territories that have adopted the Clinical Establishments (Registration and Regulation) Act, 2010. It reinforces the requirement that stem cell therapies used as standard clinical care must be limited to approved disease conditions and indications.

The ministry’s move comes amid concerns around the use and promotion of unproven stem cell interventions.

Under the regulatory framework, stem cell therapy can be provided as routine standard care only for conditions included in the approved list. Other applications may require appropriate clinical-trial and regulatory approvals.

The advisory specifically states that therapeutic use of stem cells for autism spectrum disorder is restricted to clinical trials with the necessary approvals. Unproven stem cell interventions, including stem cell therapy for autism, are not to be offered as routine, standard or commercial clinical services.

The National Medical Commission had also issued an advisory on September 5, reiterating that stem cell therapy may be offered as standard clinical care only for approved indications.

The NMC further stated that unauthorised administration, prescription, promotion or advertisement of stem cell therapy outside approved indications could constitute professional misconduct.

The Health Ministry’s latest advisory also points to potential consequences for non-compliance.

The regulatory position follows a January 2026 Supreme Court judgment concerning the legal and regulatory framework surrounding stem cell therapy. The Health Ministry said authorities should ensure compliance with applicable rules governing stem cell research and clinical use.

Stem cells have attracted significant interest because of their potential applications in regenerative medicine. Researchers are studying their possible use across several diseases and injuries.

However, the existence of scientific research into a potential treatment does not automatically mean that a therapy has been established as safe and effective for routine clinical use.

Clinical trials are designed to evaluate safety, effectiveness, appropriate dosage and other factors before a treatment can become standard care.

The government’s advisory therefore creates a distinction between approved clinical applications and experimental treatments that remain under research.

It also addresses promotion and commercialisation. Authorities have been asked to ensure that clinical establishments and healthcare professionals comply with the regulatory framework.

For patients and families considering expensive stem cell treatments, the development highlights the importance of checking whether a proposed therapy is an approved standard treatment or is being offered only within an appropriately authorised clinical trial.

The Health Ministry has asked relevant regulatory authorities and clinical establishments to ensure strict compliance with the existing framework.

Source: Ministry of Health and Family Welfare, Government of India.